US
AU
UK
KR
FR
DE
CA
JP
SE
NL
ES
NO
IT
BE
FI
HR
CHDE
OUR MISSION
To delight our customers and patients with the highest quality products and services for the treatment of Obstructive Sleep Apnea (OSA).
SomnoMed
Share Price
Last updated: 09/09/24 14:49:56
$0.405
-0.02 (-4.706%)
Today's Open
$0.42
Intraday High
$0.425
Intraday Low
$0.405
Volume
7973
About SomnoMed
We are the global leader in oral appliances for the
treatment of sleep apnea.
INVESTOR CENTRE
ASX Announcements
Investor Presentation
28-08-2024
•
PDF
FY24 Preliminary Report and FY25 Guidance
28-08-2024
•
PDF
Preliminary Final Report
28-08-2024
•
PDF
Quarterly Cashflow Report
24-07-2024
•
PDF
Quarterly Activities Report
24-07-2024
•
PDF
Completion of retail component of Entitlement Offer
03-05-2024
•
PDF
Quarterly Activities Report
29-04-2024
•
PDF
Quarterly Cashflow Report
29-04-2024
•
PDF
Replacement Prospectus
16-04-2024
•
PDF
Reinstatement to Quotation
10-04-2024
•
PDF
Completion of institutional component of Entitlement Offer
10-04-2024
•
PDF
Investor Presentation
09-04-2024
•
PDF
Prospectus Entitlement Offer
09-04-2024
•
PDF
Revised guidance and capital raising
09-04-2024
•
PDF
Update on voluntary suspension & FY24 earnings guidance
05-04-2024
•
PDF
Suspension from Quotation
02-04-2024
•
PDF
Trading Halt
27-03-2024
•
PDF
Investor presentation
28-02-2024
•
PDF
Solid start in 1H as core business revenues increase 13%
28-02-2024
•
PDF
Half Yearly Report and Accounts
28-02-2024
•
PDF
2023 Annual Report
2022 Annual Report
2021 Annual Report
2020 Annual Report
2019 Annual Report
2018 Annual Report
2017 Annual Report
2016 Annual Report
2015 Annual Report
2014 Annual Report
2013 Annual Report
2012 Annual Report
FY24 Full Year Financial Reports
28-08-2024
Annual General Meeting
TBC
Morgans_Strong_growth_across_major_sales_engines
Steady for now but potential growth driver ahead – 28 April 2022
Bridging the feedback loop to CPAP – February 22 2022
Lying in wait – 28 October 2021
Buyers on weakness – 24 August 2021
Growth mode re-engaged – 23 February 2021
A strong run but more to come – 21 October 2020
Muddy result, clearer outlook – 21 August 2019
Pain for no gain – 27 November 2018
Coming into a seasonally strong period – 21 November 2017
A transitional year – 26 April 2017
Building for growth – 18 August 2016
Moving down the supply chain – 29 May 2016
Wilsons FY24
Wilsons Equity Research Report – SOM – 26 July 2022
Retaining guidance following a patchy 3Q22 – 27 April2022
CPAP had better watch out! – 23 February 2022
Pricing in structural innovation – 25 August 2021
BUY: And suddenly, Germany – 22 August 2019
BUY: US sales growth equals margin and EPS – 25 July 2019
New BUY: Back to doing what they are world’s best at – 21 February 2019
HOLD: RSS pull-back a necessary mea culpa – 23 August 2018
BUY: Scrappy 1Q – Europe the powerhouse supporting outlook and RSS investment – 1 November 2017
BUY: US channel conflicts abating in Q4- 27 April 2017
An eye on RSS channel conflict but the core offering to prevail in US direct market – 24 February 2017
RSS taking patients in Oklahoma; good Q2 – 24 January 2017
Record Q1, SCA progress and France ratchets up reimbursement for oral appliance therapy – 19 October 2016
Organic goodness – 19 August 2016
Exciting FY17 ahead for core earnings, SCA clinic roll-out and new management – 25 July 2016
MAS Appeal – 1 June 2016
Sustained European growth underpins a solid Q2 – upgrading FY16 – 19 January 2016
SOM Research Note Update – 9 September 2022
MST Access – SOM Update – 27 July 22
MST Access – SOM Update – 2 May 2022
MST Access – SOM Initiation – 28 February 2022
Select Equities Stock Update -11 September 2019
Select Equities Stock Update – 20 January 2016
SHAREHOLDER
Contacts
Contact Investor Relations
Have a question for SomnoMed? Send us an email at the address below and our team will be in contact shortly.
Shareholder Services
Shareholders can access information such as holding balance, change of address, and annual report preferences by contacting Boardroom Pty Ltd using the form below:
